1

State‑of‑the‑Art cGMP Facilities for Cell & Gene Therapies in Hong Kong

News Discuss 
Xellera Therapeutics operates Hong Kong’s first and only multi‑product cGMP facility, featuring Grade A/B cleanrooms, integrated QC, process development, and R&D labs. The site supports flexible, multi‑product manufacturing—from early clinical to commercial scales—fully compliant with US FDA, EMA, PIC/S, and HK DoH standards. https://www.xelleratherapeutics.com/facilities/

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story